The U.S. Supreme Court has agreed to hear a closely watched dispute over whether state and local governments can continue pursuing climate-change tort claims against oil and gas companies in state court. The case arises out of Colorado litigation brought by local governments seeking to recover damages tied to alleged climate impacts, including costs associated with extreme weather, wildfire risk, and other harms.

At the center of the fight is a recurring threshold issue in climate-liability litigation: forum. Energy defendants have consistently argued that these suits belong in federal court because they implicate national and international energy policy, interstate emissions, and federal common-law principles. Plaintiffs, by contrast, have framed their claims as traditional state-law causes of action—such as nuisance, trespass, and consumer-protection theories—aimed at deceptive marketing and local harms.

The underlying Colorado matter, Boulder County Commissioners, et al v. Suncor Energy, et al, has already been a major procedural battleground. Like similar cases filed by states, cities, and counties around the country, it has generated years of litigation over removal, remand, and appellate review before the merits can even begin. The Supreme Court’s decision to step in now signals that the justices may be ready to provide broader guidance on where these cases should be heard—and potentially whether they can proceed at all in their current form.

For litigators, the case is significant well beyond climate disputes. It could clarify the scope of federal jurisdiction in cases where state-law claims are said to touch on uniquely federal interests. Any ruling on removal pathways, preemption, or federal common-law displacement could reshape not just climate cases, but also other mass tort and public nuisance suits involving nationwide commercial conduct.

For in-house counsel at energy companies and other heavily regulated businesses, the stakes are equally high. A ruling favoring defendants could narrow plaintiffs’ ability to pursue damages actions in plaintiff-friendly state venues. A ruling favoring local governments, however, could accelerate filings by municipalities and states seeking compensation for climate adaptation and disaster-response costs.

Compliance and risk teams should also be paying attention. Even though the immediate issue is procedural, the broader trend is clear: courts remain a central venue for testing corporate exposure tied to emissions, public statements, and historical business practices. A Supreme Court opinion in the Boulder County line of cases could influence litigation strategy, disclosure assessments, insurance questions, and reserve planning across multiple sectors.

For legal professionals tracking this area, the Supreme Court’s review marks a pivotal moment in climate-liability jurisprudence. The outcome may determine not only the venue for these claims, but the practical future of climate damages litigation nationwide.

Toyota Motor Corporation has filed a new inter partes review petition at the Patent Trial and Appeal Board, opening proceeding IPR2026-00333 on April 7, 2026. The filing places at issue the validity of a patent that, while not identified in the docket caption itself, is now the subject of a formal PTAB challenge by one of the world’s largest automotive companies. For patent owners and accused infringers alike, that alone makes this proceeding worth watching closely.

At this stage, the key public-facing details are the petitioner, the forum, and the timing. The petitioner is Toyota Motor Corporation, and the case will proceed before the Patent Trial and Appeal Board, where the company is asking the Board to institute review of challenged patent claims. As with other IPRs, the patent owner will have an opportunity to file a preliminary response, after which the Board will decide whether Toyota has shown a reasonable likelihood of prevailing on at least one challenged claim.

The specific grounds for review are expected to center on anticipation and/or obviousness under 35 U.S.C. §§ 102 and 103 based on prior art patents and printed publications—the standard framework for IPR practice. Once the petition and accompanying exhibits are fully available, practitioners will want to examine how Toyota frames its invalidity theories, whether it relies on a single primary reference or a multi-reference obviousness combination, and how it addresses any claim-construction or priority-date issues that could determine institution.

This case is especially relevant for patent practitioners and in-house IP counsel because automotive-sector PTAB disputes often involve technologies with broader commercial significance, including vehicle systems, software, sensing, communications, electrification, or manufacturing processes. A filing by Toyota may also signal parallel district court litigation, licensing pressure, supplier exposure, or strategic efforts to clear freedom-to-operate concerns. Even before institution, the petition can provide an early look at how a major operating company is evaluating prior art and litigation risk.

PTAB watchers should also follow the procedural developments: whether Toyota seeks review of all asserted claims or a narrower subset, whether discretionary-denial issues arise, and whether the patent owner responds with strong objective-indicia evidence or amendment strategies. Those issues can shape settlement dynamics and provide useful guidance for future petition drafting.

For attorneys tracking new PTAB filings, this is a matter to keep on the radar as the record develops and the challenged patent, asserted claims, and prior-art grounds come into sharper focus.

View full case on Docket Alarm

Litigation over mifepristone is poised to remain one of the most closely watched legal battlegrounds of 2026, with challenges unfolding across multiple fronts at once: federal agency authority, state abortion restrictions, drug distribution rules, and preemption. What makes these disputes especially significant is that they are no longer confined to a single high-profile lawsuit. Instead, they now form a broader, fast-moving matrix of cases involving generic manufacturers such as GenBioPro, state officials, providers, and advocacy groups in courts around the country.

At the center of many of these fights is a basic but consequential legal question: how far can states go in restricting access to an FDA-approved drug? That issue has implications well beyond abortion law. For judges and litigants, mifepristone cases are becoming a proving ground for arguments about the scope of federal supremacy, the limits of state police powers, and the degree of deference owed to the FDA’s scientific and regulatory judgments.

The appellate posture also matters. With federal appellate courts, including the Fourth Circuit, expected to remain active venues for these disputes, the law may continue to develop unevenly across jurisdictions. That creates a patchwork environment in which providers, pharmacies, telehealth companies, and manufacturers must navigate conflicting obligations and shifting enforcement risks. Even where a particular restriction survives in one state, parallel challenges elsewhere may produce very different outcomes on standing, preemption, or administrative law grounds.

For litigators, this area offers a dense mix of issues: emergency relief, forum selection, sovereign enforcement questions, and the interaction between federal regulatory schemes and state statutory regimes. In-house counsel and compliance teams should also be paying close attention. Companies involved in manufacturing, prescribing, dispensing, shipping, or reimbursing reproductive-health medications face substantial uncertainty around distribution channels, labeling-related arguments, and state-specific compliance exposure. Risk assessments may need to be updated not just for substantive law changes, but for litigation-triggered operational disruptions.

The practical stakes are equally high. Mifepristone litigation affects provider access, patient access, and the viability of mail-order and telemedicine models. But from a legal-industry perspective, the broader significance is that these cases are shaping doctrine in administrative law, constitutional structure, and products regulation all at once.

As 2026 unfolds, legal professionals should expect continued motion practice, appellate activity, and strategic case filings designed to test where FDA authority ends and state restriction power begins. That makes this not just an abortion-rights story, but one of the most consequential regulatory and federalism disputes on the litigation calendar.